IBRANCE 75 MG — DIN 02493535
PALBOCICLIB : 75 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is IBRANCE?
IBRANCE 75 MG contains PALBOCICLIB : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02493535, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IBRANCE used for?
IBRANCE (palbociclib) is indicated for: the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression after prior endocrine therapy. Pre/perimenopausal women and men treated with the combination IBRANCE plus aromatase inhibitor therapy, and pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with a luteinizing hormone releasing hormone (LHRH) agonist. Clinical effectiveness of IBRANCE in combination with an aromatase inhibitor is based on the benefit observed in patients treated with IBRANCE in combination with letrozole for the treatment of postmenopausal women with advanced breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Palbociclib cost around the world?
Palbociclib is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 11 | 26 | SAR███.██ |
| Bahrain | retail (max) | 3 | 12 | BHD███.██ |
| South Africa | single exit price | 9 | 9 | ZAR███.██ |
| United Arab Emirates | public | 6 | 6 | AED███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Romania | max producer price | 3 | 6 | RON███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 3 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 3 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 3 | CZK███.██ |
| Iceland | max wholesale | 1 | 3 | ISK███.██ |
| Italy | ex-factory (classe H) | 3 | 3 | EUR███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
89 pack listings across 56 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Palbociclib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Palbociclib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Palbociclib, across 12 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 6 | 3 | IBRANCE | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 3 | PMS-PALBOCICLIB | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 3 | 3 | TARO-PALBOCICLIB | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 75 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Box containing 3 weekly blister packs of 7 tablets each (21 tablets total) for 125 mg, 100 mg, and 75 mg strengths. |
| Storage | Store at 15 °C to 30°C in the original blister pack to protect from moisture. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Palbociclib |
|---|---|
| ATC code | L01EF01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02493535 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2493535 |
| Brand name | IBRANCE |
| Generic / active ingredient | PALBOCICLIB : 75 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | L01EF01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01EF |
| Current status | MARKETED |
| Status date | 21-Sep-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dose of IBRANCE (palbociclib) is a 125 mg-tablet taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. IBRANCE is used in combination with an aromatase inhibitor or fulvestrant. For full dosing instructions of the selected aromatase inhibitor-or fulvestrant, please consult the corresponding Product Monographs. Management of some adverse reactions may require temporary dose interruptions/delays and/or dose reductions, or permanent discontinuation of IBRANCE as per dose reduction schedules provided in Table 1, 2, and 3. IBRANCE tablets may be taken with or without food. Patients should be advised to take their dose at approximately the same time each day. Continue the treatment as long as the patient is deriving clinical benefit from therapy. If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time. IBRANCE tablets should be swallowed whole (do not chew, crush or split the tablets prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. Do not use IBRANCE if you are allergic to palbociclib or any of the other ingredients of IBRANCE.
Warnings and precautions
IBRANCE (palbociclib) should be prescribed and managed by a qualified physician who is experienced in the use of anti-cancer agents. The following is a significant adverse drug reaction identified in clinical trials conducted with IBRANCE: Neutropenia. Permanently discontinue IBRANCE in patients with severe interstitial lung disease (ILD) or pneumonitis. IBRANCE may predispose patients to infections. Physicians should be aware of the increased risk of infection with IBRANCE and should inform patients to promptly report any episodes of fever. Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with IBRANCE when taken in combination with endocrine therapy. Patients should be monitored for pulmonary symptoms indicative of ILD/pneumonitis (e.g. hypoxia, cough, dyspnea). In patients who have new or worsening respiratory symptoms and are suspected to have developed ILD/pneumonitis, interrupt IBRANCE immediately and evaluate the patient. IBRANCE should be permanently discontinued in patients diagnosed with severe drug-related ILD/pneumonitis. Across clinical trials, venous thromboembolic events (VTEs) were reported. Monitor patients for signs and symptoms of VTEs and treat as medically appropriate. No studies of the effects of IBRANCE (palbociclib) on the ability to drive or operate machinery have been conducted. However, since fatigue and dizziness have been reported with the use of IBRANCE, patients should exercise caution when driving or operating machinery while taking IBRANCE.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| IBRANCE | 100 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02493543 |
| IBRANCE | 125 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02493551 |
| PMS-PALBOCICLIB | 75 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02552124 |
| PMS-PALBOCICLIB | 125 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02552140 |
| PMS-PALBOCICLIB | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02552132 |
| TARO-PALBOCICLIB | 75 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | 02547635 |
| TARO-PALBOCICLIB | 100 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | 02547643 |
| TARO-PALBOCICLIB | 125 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | 02547651 |
| IBRANCE | 75 MG | CAPSULE | PFIZER CANADA ULC | CANCELLED POST MARKET | 02453150 |
| IBRANCE | 125 MG | CAPSULE | PFIZER CANADA ULC | CANCELLED POST MARKET | 02453177 |
2 · Same class — other molecules in ATC L01EF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Palbociclib | IBRANCE · PMS-PALBOCICLIB · TARO-PALBOCICLIB | 12 | 9 | Yes |
| Abemaciclib | VERZENIO | 4 | 4 | Yes |
| Ribociclib | KISQALI | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · +17 more | 80 | 64 |
| L01EA | Asciminib · Bosutinib · Dasatinib · Imatinib · Nilotinib · +1 more | 73 | 57 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01ED | Alectinib · Brigatinib · Ceritinib · Crizotinib · Lorlatinib | 10 | 10 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EL | Acalabrutinib · Ibrutinib · Zanubrutinib | 10 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is IBRANCE called?
Also recorded in Canada as: palbociclib 100 MG Oral Capsule [Ibrance] (US), palbociclib 125 MG Oral Capsule [Ibrance] (US), palbociclib 75 MG Oral Capsule [Ibrance] (US), palbociclib 100 MG Oral Tablet [Ibrance] (US), palbociclib 125 MG Oral Tablet [Ibrance] (US), palbociclib 75 MG Oral Tablet [Ibrance] (US), palbociclib 100 MG Oral Capsule (US), palbociclib 125 MG Oral Capsule (US), palbociclib 75 MG Oral Capsule (US), palbociclib 100 MG Oral Tablet (US), palbociclib 125 MG Oral Tablet (US), palbociclib 75 MG Oral Tablet (US), PALBOCICLIB (US), PALBOCICLIB (UK).
The same molecule, Palbociclib, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cryptario | Latin | Bahrain, Saudi Arabia |
| Papillio | Latin | Bahrain, Saudi Arabia |
| chinasi | Latin | Saudi Arabia |
| Innolib | Latin | Saudi Arabia |
| Pabrolib | Latin | Saudi Arabia |
| Palpocent | Latin | Saudi Arabia |
| Sekpal | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.